地舒单抗在长期血液透析中逆转主动脉弓钙化
本研究在单中心观察性研究中纳入58例透析龄8年的患者,其中28例每6个月接受地舒单抗治疗。观察30个月后,对照组主动脉弓钙化比例从29.4%增至46.25%,而地舒单抗组从25.0%显著降至20.0%(P < 0.01)。结论认为长期使用地舒单抗可逆转或治疗血液透析患者的主动脉弓钙化。
要点
- 长期地舒单抗治疗可显著降低血液透析患者的主动脉弓钙化比例。
- 地舒单抗的脱钙效应在开始治疗后12个月内未观察到。
- 对照组主动脉弓钙化比例在30个月内从29.4%增至46.25%。
核心结论
- 长期使用地舒单抗可有效逆转或治疗血液透析患者的主动脉弓钙化。
研究设计与样本
- 单中心观察性研究,2009至2020年纳入58例透析龄8年的患者,其中28例每6个月接受地舒单抗治疗。
主要发现
- 观察30个月后,对照组主动脉弓钙化比例从29.4%增至46.25%,地舒单抗组从25.0%显著降至20.0%(P < 0.01)。
- 地舒单抗的脱钙效应在开始治疗后12个月内未观察到。
- 两组基线血生化数据无差异,观察30个月后矿物质代谢出现差异。
临床怎么用
- 对于长期血液透析患者,可考虑使用地舒单抗以逆转主动脉弓钙化,但需注意效应可能在12个月后才显现。
局限性
- 本研究为单中心观察性研究,样本量较小(58例),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Aortic arch calcification (AoAC) is related closely to mortality risk in patients undergoing maintenance dialysis. Recent experimentally obtained data suggest that osteoprotegerin/receptor activator for nuclear factor κB ligand signal transmission plays a role in de novo chondrogenic transition of vascular cells leading to calcification that is unrelated to bone metabolism. This study investigated the long-term effects of denosumab, an osteoprotegerin mimic peptide, on AoAC. METHODS: This study examined 58 patients with an 8 year vintage of dialysis at 1 center for observational study during 2009 to 2020. Denosumab was administered to 28 patients every 6 months. Blood chemical data were used. AoAC proportions were measured using a simple but computed tomography-equivalent computer-based chest X-ray analysis (calcified pieces of areas around the aorta). RESULTS: Blood chemical data of the control and denosumab groups that did not differ at the start showed differences of mineral metabolism after 30 months of observation. Remarkably, the AoAC proportion increased from 29.4% to 46.25% in the control group but decreased significantly from 25.0% to 20.0% (P < 0.01) in the denosumab group. Denosumab effects on decalcification were not observed 12 months after initiation. CONCLUSION: We conclude that long-term use of denosumab is effective to reverse or treat AoAC in patients undergoing hemodialysis.
引用
- Suzuki S, Suzuki M, Hanafusa N, et al. Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis. Kidney Int Rep. 2020. PMID: 33732975. doi:10.1016/j.ekir.2020.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。